Precision BioSciences Valuation
| DTIL Stock | USD 3.96 0.03 0.75% |
At this time, the company appears to be undervalued. Precision BioSciences holds a recent Real Value of $11.06 per share. The prevailing price of the company is $3.96. Our model determines the value of Precision BioSciences from analyzing the company fundamentals such as Shares Outstanding of 24.07 M, return on equity of -2.05, and Shares Owned By Institutions of 42.50 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Precision BioSciences' valuation include:
Price Book 5.7017 | Enterprise Value | Enterprise Value Ebitda (0.27) | Price Sales 137.4297 | Forward PE 11.7786 |
Undervalued
Today
Please note that Precision BioSciences' price fluctuation is somewhat reliable at this time. Calculation of the real value of Precision BioSciences is based on 3 months time horizon. Increasing Precision BioSciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Precision stock is determined by what a typical buyer is willing to pay for full or partial control of Precision BioSciences. Since Precision BioSciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Precision Stock. However, Precision BioSciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.96 | Real 11.06 | Target 32.5 | Hype 4.11 | Naive 3.9 |
The intrinsic value of Precision BioSciences' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Precision BioSciences' stock price.
Estimating the potential upside or downside of Precision BioSciences helps investors to forecast how Precision stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Precision BioSciences more accurately as focusing exclusively on Precision BioSciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Precision BioSciences' intrinsic value based on its ongoing forecasts of Precision BioSciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Precision BioSciences' closest peers.
Precision BioSciences Cash |
|
Precision BioSciences Total Value Analysis
Precision BioSciences is currently forecasted to have valuation of 79.1 M with market capitalization of 95.93 M, debt of 30.05 M, and cash on hands of 184.14 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Precision BioSciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
79.1 M | 95.93 M | 30.05 M | 184.14 M |
Precision BioSciences Investor Information
About 43.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 8.96. Precision BioSciences had not issued any dividends in recent years. The entity had 1:30 split on the 14th of February 2024. Based on the key indicators related to Precision BioSciences' liquidity, profitability, solvency, and operating efficiency, Precision BioSciences is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Precision BioSciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Precision BioSciences has an asset utilization ratio of 50.37 percent. This suggests that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Precision BioSciences is more efficient with each dollar of assets it utilizes for everyday operations.Precision BioSciences Profitability Analysis
Based on Precision BioSciences' profitability indicators, Precision BioSciences is yielding more profit at this time then in previous quarter. It has a moderate odds of reporting better profitability numbers in March. Profitability indicators assess Precision BioSciences' ability to earn profits and add value for shareholders.Net Income | First Reported 2017-12-31 | Previous Quarter -23.5 M | Current Value -21.8 M | Quarterly Volatility 14.3 M |
For Precision BioSciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Precision BioSciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Precision BioSciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Precision BioSciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Precision BioSciences over time as well as its relative position and ranking within its peers.
Precision BioSciences Earnings per Share Projection vs Actual
The next projected EPS of Precision BioSciences is estimated to be -1.540825 with future projections ranging from a low of -1.6675 to a high of -1.455. Precision BioSciences' most recent 12-month trailing earnings per share (EPS TTM) is at -8.96. Please be aware that the consensus of earnings estimates for Precision BioSciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Precision BioSciences Earnings Estimation Breakdown
The calculation of Precision BioSciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Precision BioSciences is estimated to be -1.540825 with the future projection ranging from a low of -1.6675 to a high of -1.455. Please be aware that this consensus of annual earnings estimates for Precision BioSciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.67 Lowest | Expected EPS | -1.46 Highest |
Precision BioSciences Earnings Projection Consensus
Suppose the current estimates of Precision BioSciences' value are higher than the current market price of the Precision BioSciences stock. In this case, investors may conclude that Precision BioSciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Precision BioSciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 39.12% | -1.84 | -1.540825 | -8.96 |
Precision BioSciences Ownership Allocation
Precision BioSciences owns a total of 24.07 Million outstanding shares. 30% of Precision BioSciences outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Precision BioSciences Profitability Analysis
The company reported the previous year's revenue of 68.7 M. Net Income was 7.17 M with profit before overhead, payroll, taxes, and interest of 698 K.About Precision BioSciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Precision BioSciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Precision BioSciences based exclusively on its fundamental and basic technical indicators. By analyzing Precision BioSciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Precision BioSciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Precision BioSciences. We calculate exposure to Precision BioSciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Precision BioSciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 79 M | 40.2 M | |
| Pretax Profit Margin | 0.09 | 0.10 | |
| Operating Profit Margin | (0.34) | (0.36) | |
| Net Profit Margin | 0.09 | 0.10 |
Precision BioSciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Precision BioSciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.9 M | |
| Forward Price Earnings | 11.7786 |
Precision BioSciences Current Valuation Indicators
Precision BioSciences' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Precision BioSciences' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Precision BioSciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Precision BioSciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Precision BioSciences' worth.When determining whether Precision BioSciences is a strong investment it is important to analyze Precision BioSciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Precision BioSciences' future performance. For an informed investment choice regarding Precision Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.96) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.